Drug intelligence / Profile preview

Fibrinogen Concentrate + Prothrombin Complex Concentrate + Factor XIII Concentrate

Development stage: Unknown
Lead developer: Republican Research and Practical Center of Transfusion and Medical Biotechnologies
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

This combination is used to treat coagulopathic bleeding by correcting deficiencies in fibrinogen, prothrombin, and factor XIII. Fibrinogen is converted into fibrin by thrombin, forming a clot. Prothrombin complex concentrates (PCCs) contain factors II, IX, and X, which are essential for the coagulation cascade. Factor XIII stabilizes the fibrin clot by cross-linking fibrin polymers, making it more resistant to fibrinolysis.

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)SERPINF2 (Alpha-2-antiplasmin)F2 (Thrombin)

Beyond the preview

Go deeper on Fibrinogen Concentrate + Prothrombin Complex Concentrate + Factor XIII Concentrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrinogen Concentrate + Prothrombin Complex Concentrate + Factor XIII Concentrate.

Explore the full profile